Patents by Inventor Shai Rahimipour

Shai Rahimipour has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9770418
    Abstract: The present invention provides a sonochemical irradiation-based method for the preparation of polydopamine (PDA) nanocapsules having reduced wall thickness and uniform size distribution, which may further comprise at least one payload; nanocapsules obtained by this method; and compositions thereof. Such compositions may be formulated for different purposes, e.g., as pharmaceutical compositions for various therapeutic or diagnostic purposes.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: September 26, 2017
    Assignee: BAR-ILAN UNIVERSITY
    Inventors: Shai Rahimipour, Gil Yeroslavsky, Michal Richman
  • Publication number: 20170088585
    Abstract: Cyclic D,L-?-peptides were shown to have an anti-amyloid aggregation effect. The cyclic peptide (designated cyclic peptide-2) having the sequence [1JwHsK], had a drastic effect on amyloid aggregation. However, the linear equivalent of cyclic peptide-2 did not inhibit amyloid formation. Cyclic peptide 2 was also effective in reducing A?-induced toxicity in PC12 cells. According to embodiments of the invention, cyclic peptides may comprise between 6 or 8 amino acids. In an embodiment, half of the amino acid residues are in the D-formation, and the other half are in the L-formation. In an embodiment of the invention, the amino acids alternate between the D and L-formations.
    Type: Application
    Filed: October 10, 2016
    Publication date: March 30, 2017
    Inventor: Shai RAHIMIPOUR
  • Patent number: 9504759
    Abstract: An aspect of embodiments of the invention relates to surface modified proteinaceous spherical particles (SMOP). SMOPs according to an embodiment of the invention may comprise a protein layer and an amyloid-binding moiety bound to the protein. In an embodiment, the protein layer is spherical in shape and comprises proteins linked to each other by disulfide bonds. It is suggested that SMOPs are effective in preventing formation of amyloid and aggregation of A? when administered to a patient in need thereof.
    Type: Grant
    Filed: August 8, 2012
    Date of Patent: November 29, 2016
    Assignee: BAR-ILAN UNIVERSITY
    Inventor: Shai Rahimipour
  • Publication number: 20140205668
    Abstract: An aspect of embodiments of the invention relates to surface modified proteinaceous spherical particles (SMOP). SMOPs according to an embodiment of the invention may comprise a protein layer and an amyloid-binding moiety bound to the protein. In an embodiment, the protein layer is spherical in shape and comprises proteins linked to each other by disulfide bonds. It is suggested that SMOPs are effective in preventing formation of amyloid and aggregation of A? when administered to a patient in need thereof.
    Type: Application
    Filed: August 8, 2012
    Publication date: July 24, 2014
    Applicant: BAR-ILAN UNIVERSITY
    Inventors: Shai Rahimipour, Michal Richman
  • Publication number: 20140193489
    Abstract: The present invention provides a sonochemical irradiation-based method for the preparation of polydopamine (PDA) nanocapsules having reduced wall thickness and uniform size distribution, which may further comprise at least one payload; nanocapsules obtained by this method; and compositions thereof. Such compositions may be formulated for different purposes, e.g., as pharmaceutical compositions for various therapeutic or diagnostic purposes.
    Type: Application
    Filed: January 7, 2014
    Publication date: July 10, 2014
    Applicant: BAR-ILAN UNIVERSITY
    Inventors: Shai Rahimipour, Gil Yeroslavsky, Michal Richman
  • Publication number: 20060100154
    Abstract: The present invention relates to the design, synthesis and biological evaluation of potent long-acting gonadotropin-releasing hormone (GnRH) analogs including agonists and antagonists comprising a GnRH peptide conjugated to emodic acid or an emodic acid derivative. These long acting analogs bind to GnRH receptors with high affinity and are devoid of any toxicity or antiproliferative effects. The present invention further relates to therapeutic uses of these GnRII analogs as contraceptives, in controlling fertility and in treating and/or preventing sex-hormone dependent diseases or conditions.
    Type: Application
    Filed: October 13, 2005
    Publication date: May 11, 2006
    Applicant: YEDA RESEARCH AND DEVELOPMENT CO
    Inventors: Yitzhak Koch, Matityahu Fridkin, Shai Rahimipour